DeepSeq.AI
DeepSeq.AI, founded in 2019 and based in California, is an AI protein drug discovery company that combines high-throughput wet-lab assays with protein language models and generative AI to predict and optimize biologics properties (affinity, specificity, immunogenicity, PK, manufacturability) for large biopharma partners.
About
DeepSeq.AI, founded in 2019 and based in California, is an AI protein drug discovery company that combines high-throughput wet-lab assays with protein language models and generative AI to predict and optimize biologics properties (affinity, specificity, immunogenicity, PK, manufacturability) for large biopharma partners. It has DARPA and NSF funding, accelerator backing from Merck Digital Sciences Studio, StartX and SkyDeck, and investment from Illumina Ventures and Zaka VC.
Capital graph
Founders / team· 2
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- DeepSeq.AI
DeepSeq.AI, founded in 2019 and based in California, is an AI protein drug discovery company that combines high-throughput wet-lab assays with protein language models and generative AI to predict and optimize biologics properties (affinity, specificity, immunogenicity, PK, manufacturability) for large biopharma partners. It has DARPA and NSF funding, accelerator backing from Merck Digital Sciences Studio, StartX and SkyDeck, and investment from Illumina Ventures and Zaka VC.
$620K
$620K
United States
BusinessLatest roundTotal raisedDate- Diffuse Bio
Diffuse Bio is a generative-AI protein design company founded in 2022 and backed by Y Combinator (W23). It pairs diffusion-model design software (DiffuseSandbox) with wet-lab screening (RamaX) for therapeutic proteins, vaccines and enzymes, and is expanding into generating verified biological reward signals at scale for AI models.
$500K
$500K - Terray Therapeutics
Combines AI with wet lab science to discover new small-molecule drugs
Undisclosed · $120M · 2024-10
$120M - Tahoe Therapeutics
Develops large-scale single-cell datasets to train AI models of human cells for drug discovery
Undisclosed · $30M · 2025-08
$30M
China
BusinessLatest roundTotal raisedDate- ATLATL Innovation Center
ATLATL is a life-science innovation and shared-lab operator founded in 2017 in Shanghai's Zhangjiang, providing move-in-ready labs, on-site CRO services and R&D platforms (gene and cell therapy, AI-assisted drug screening, large-molecule research) to early-stage biotech companies across Shanghai, Beijing, Shenzhen, Hong Kong, Singapore and Australia.
— - 途深智合
AI protein design platform; conversational protein design platforms ProteinNova/ProteinEngine covering site-directed mutagenesis, enzyme engineering, de novo design, antibody structure and more
Angel · $1M · 2025-09
$1M - Matwings Technology
Protein design model MatwingsVenus with an automated lab platform, doing enzyme mining and directed evolution for universities and pharma companies
Series A · 2026-07
—
Europe
BusinessLatest roundTotal raisedDate- Isomorphic Labs
AI-driven drug design platform (IsoDDE engine): uses AlphaFold-based technology to predict protein structures and design new drug molecules; builds its own therapeutic pipeline and conducts joint R&D with large pharmaceutical companies
Series B · $2.7B · 2026-05
$2.7B - Rivercell
In-house automated wet lab generating large-scale single-cell perturbation data to train "AI virtual cell" models that predict human cell responses to drugs and genetic changes
Seed · 2026-10
— - Basecamp Research
Trains the EDEN foundation model on proprietary biodiversity genomic data and uses AI to design proteins and in vivo cell therapies
Series C · $200M · 2026-09
$200M
Other / unspecified
BusinessLatest roundTotal raisedDate- Halmos Labs
AI-driven automated R&D systems for biotech and pharma that simulate experimental outcomes before wet-lab work and recommend the experiments that most reduce uncertainty
— - Galux
AI plus physics-based protein/antibody design platform (GaluxDesign) for drug discovery
Series B · $58M · 2026-02
$58M - 深度细胞
Combines AI with multiscale molecular physics to build a "virtual cell world model" for disease mechanism discovery and drug design
Seed · $14M · 2026-08
$14M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 22 in United States
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.